Sinequan

Market Realities & Availability

Basic Sinequan Information

• INN (International Nonproprietary Name): Doxepin.
• Brand Names Available In United Kingdom: Sinequan (listed for UK/export), generics from manufacturers such as Mylan and Teva; Silenor appears as a branded insomnia tablet in other markets.
• ATC Code: N06AA12 — tricyclic antidepressant (non‑selective monoamine reuptake inhibitor).
• Forms & Dosages: Capsules 10, 25, 50, 75, 100 mg; oral solution 10 mg/mL in some markets; Silenor tablets 3 mg and 6 mg for insomnia.
• Manufacturers In United Kingdom: Major generic suppliers include Mylan and Teva; local generics may be imported or supplied by UK wholesalers.
• Registration Status In United Kingdom: Registered as prescription only (Rx) with generic approval prevalent.
• OTC / Rx Classification: Prescription only (Rx) across major markets including the UK.

What The Market Looks Like Now

Are branded packs easy to find and which ones are common?

Sinequan remains a widely recognised name, but brand availability varies by market and the Sinequan brand has been discontinued in the USA with generics supplying the demand.

Generics by Mylan, Teva and local manufacturers supply capsules globally and are commonly dispensed in the UK by community chains and independent pharmacies.

The ATC code N06AA12 classifies doxepin as a tricyclic antidepressant, which helps pharmacists locate product information and SPCs when sourcing stock.

In the UK, doxepin is prescription-only and regulated by the MHRA, and patients obtain supplies through NHS prescriptions or private prescriptions.

Devolved NHS systems affect cost: prescriptions are free in Scotland, Wales and Northern Ireland, while England uses a standard charge unless exemptions apply.

Online pharmacies and e‑prescriptions are growing, and major chains such as Boots, LloydsPharmacy and Superdrug commonly dispense generic doxepin capsules with pharmacist consultations.

Patient Experiences & Common Use-Cases

Real-World Use And Reported Effects

Who typically ends up prescribed doxepin and why?

Patients most often see doxepin prescribed for major depressive disorder and anxiety-related depression, while low doses (Silenor) are used specifically for insomnia.

Many people report an early sedative benefit that helps with sleep onset and anxiety-driven insomnia, often noticed within days.

Others describe troublesome daytime drowsiness, dry mouth and blurred vision, which may prompt dose timing changes or dose reduction.

Mood improvements may begin around 1–3 weeks, with fuller antidepressant effects taking several weeks in some patients.

Elderly patients commonly report increased confusion, dizziness or balance issues, and clinicians frequently reduce dose or switch to alternatives for frail patients.

For insomnia, Silenor 3–6 mg at bedtime provides sedating benefit with fewer daytime effects than higher TCA doses when used specifically for sleep.

Keeping a simple patient diary is valuable; record sleep latency, total sleep time, daytime sleepiness, PHQ‑9/GAD‑7 scores and a side‑effect checklist for the first 6–12 weeks.

Indications, Who It’s For And Contraindications

Indications And Absolute Contraindications

What conditions is doxepin indicated for and who should never take it?

Primary indications include major depressive disorder and anxiety-related depression, with low-dose formulations used for insomnia (Silenor brand in some markets).

Absolute contraindications are: known doxepin or tricyclic antidepressant hypersensitivity, narrow-angle glaucoma, urinary retention, and recent MAOI use within the past 14 days.

Relative contraindications include advanced age, significant cardiac conduction disease or arrhythmias, severe hepatic or renal impairment, severe prostatic hypertrophy, and a history of suicidality.

Pregnancy and lactation are relative contraindications where specialist advice is required and use should be limited to situations where benefits outweigh risks.

Prescribers in the UK must follow MHRA guidance and balance individual risks and benefits, documenting rationale for starting or continuing therapy.

When a contraindication is present, pharmacists should flag and discuss the issue with the prescriber before dispensing.

Formulations, Strengths And Packaging

What You Can Expect In A Pharmacy

Which forms and pack types will a patient see on the shelf?

Doxepin is supplied commonly as capsules in strengths of 10, 25, 50, 75 and 100 mg, which are the most widely dispensed format.

Some markets provide an oral solution at 10 mg/mL useful for titration or for patients with swallowing difficulties.

For insomnia, Silenor tablets are available as 3 mg and 6 mg strengths and are marketed specifically for sleep disturbance.

Packaging varies by manufacturer and distributor and may include blister packs, bottles of capsules or pharmacy bulk containers for dispensing.

Brand examples include Sinequan (capsules), Silenor (low‑dose tablets), Quitaxon (Spain) and Doquel (Australia).

For a UK product page, include a pack image, a strengths table and a quick selector advising which strength may suit the prescribed indication.

Standard Dosing By Condition & Titration

Practical Dosing Guidance

How is doxepin started and adjusted in everyday practice?

For adults with depression or anxiety, a common starting dose is around 75 mg per day, taken either divided or at night, with a usual range of 75–150 mg/day and doses up to 300 mg/day for severe cases.

For insomnia, Silenor dosing is 3–6 mg at bedtime and is not comparable to higher antidepressant doses in terms of anticholinergic risk.

Children under 12 are not recommended to use doxepin, and adolescents should be treated with the lowest effective dose and close monitoring.

Elderly patients are more sensitive to anticholinergic and sedative effects, so start low (for example 25–50 mg/day) and titrate carefully.

Hepatic or renal impairment necessitates reduced starting doses and slower titration with monitoring of effects and side effects.

Example titration steps: start 25–50 mg/day, reassess at 1 week for sedation and orthostasis, then increase by 25–50 mg every 1–2 weeks until response or limit tolerated dose.

Monitor blood pressure, heart rate and anticholinergic burden during titration, and document any dose changes for repeat prescribing.

Practical First-Fill Advice And Pharmacy Counselling

What Pharmacists Should Tell Patients

What should be covered at the first dispense so patients start safely?

Advise patients about prescription status, expected onset of antidepressant effect (often 1–3 weeks), and common early effects such as sedation and dry mouth.

Explain the action for missed doses: take as soon as remembered unless the next dose is due, and do not double doses to catch up.

Counsel patients to avoid alcohol and to be cautious with driving or operating machinery until they know how doxepin affects them.

For elderly or cardiac comorbidity, recommend baseline ECG where appropriate and a medicines review for QT‑prolonging agents.

Provide a written patient information sheet, a sleep/mood diary template and a checklist of symptoms to report (urinary retention, severe dizziness, chest pain or worsening mood).

Explain NHS prescription charges and devolved exemptions, and advise how to arrange repeats via electronic repeatable prescriptions or GP appointments.

Offer a pharmacy follow-up at 1–2 weeks to review tolerability and any side effects, and document counselling on the patient record.

Drug Interactions & Concomitant Medicines

Key Interactions To Flag

Which drug combinations are high risk and require action?

MAOI use within the previous 14 days is absolutely contraindicated due to the risk of severe interactions.

Concomitant serotonergic drugs increase the risk of serotonin syndrome and should be co‑prescribed only with careful clinical review.

Anticholinergic agents such as some antihistamines and antipsychotics add to dry mouth, constipation, urinary retention and confusion risks.

Caution is required with QT‑prolonging drugs and with CNS depressants such as benzodiazepines, opioids and alcohol because of additive sedation and respiratory depression.

Doxepin is metabolised partly by CYP enzymes and interacting drugs that inhibit CYP2D6 or CYP2C19 (for example fluoxetine, paroxetine) may increase plasma doxepin concentrations and require dose adjustments or monitoring.

Perform medicines reconciliation for other antidepressants, antipsychotics and antiarrhythmics, and consult the prescriber about strong CYP inhibitors or inducers.

• High-Risk Drugs: MAOIs — do not co‑prescribe.
• Monitor/Adjust: SSRIs that inhibit CYP2D6, QT‑prolonging agents, strong CYP inhibitors.

Side-Effect Profile, Monitoring And Minimising Risk

Common Vs Serious Effects And Monitoring Plan

What side effects should patients expect and which require urgent care?

Common adverse effects include drowsiness, dry mouth, dizziness, blurred vision, constipation, urinary retention, weight gain and orthostatic hypotension.

Serious but less frequent risks are cardiac arrhythmias, seizures and severe anticholinergic effects; any sudden chest pain, palpitations or loss of consciousness needs urgent assessment.

Baseline monitoring should include blood pressure, heart rate and orthostatic vitals, and an ECG for patients with existing cardiac risk factors.

Mood and suicidality checks are important during the first 4–12 weeks after starting or changing dose.

For elderly patients perform a fall‑risk assessment and arrange medication review at each change in therapy.

Simple strategies to reduce risk include starting low, dosing at night to limit daytime sedation, advising hydration for dry mouth and a bowel regimen to prevent constipation.

Overdose, Missed Dose And Withdrawal

Emergency And Routine Advice

What should patients and carers do in an emergency or for routine missed doses?

Overdose with doxepin can cause severe drowsiness, confusion, cardiac arrhythmias and seizures and requires immediate medical attention and emergency services notification of possible TCA toxicity.

Management of overdose is supportive and carried out in hospital settings with monitoring and symptomatic treatment.

For a missed dose, take it as soon as remembered unless it is close to the next planned dose, and do not double up doses.

When stopping treatment, a gradual taper is recommended to reduce withdrawal symptoms and rebound depression; the taper schedule should be tailored to the current dose and treatment duration.

Carers should be advised to monitor mood closely and watch for increased suicidal thoughts during initiation, dose changes and withdrawal.

Provide clear written instructions for missed doses and emergency contact numbers at the first dispense.

Storage, Transport And Handling

Safe Storage And Pharmacy Logistics

How should doxepin be stored and handled in pharmacy and at home?

Store doxepin at room temperature, generally 15–30°C, protected from moisture and excessive heat.

Transport products in original packaging to avoid contamination or deterioration and to preserve labelling and batch information.

Pharmacies should follow supplier handling guidance and ensure bulk bottles are clearly labelled with batch and expiry details prior to dispensing.

For online orders use discreet packaging and consider temperature control measures in summer to avoid exposure to high heat during transit.

Ask patients to return unused medicine to pharmacy take‑back schemes rather than flushing them away.

Inspect capsules or tablets for discolouration or damage before re‑dispensing after storage or shipment.

Comparative Positioning Vs Alternatives

When Doxepin Is Chosen Over SSRIs Or Other TCAs

Why might a clinician choose doxepin instead of an SSRI or another tricyclic?

Doxepin is chosen when sedative antidepressant properties are desirable, for example depressed patients with prominent insomnia or anxiety‑related sleep disturbance.

SSRIs such as sertraline and fluoxetine are generally first‑line for depression because of more favourable tolerability profiles, but doxepin can be effective when SSRIs are not tolerated or effective.

Low‑dose doxepin (Silenor) may outperform other agents for chronic insomnia where a specifically sedating antidepressant effect is the goal.

Comparable TCAs include amitriptyline, nortriptyline and imipramine; choice depends on comorbidities, side‑effect profiles and cardiac risk.

Manufacturers, Supply Chain & Generics

Brands And Sourcing Notes Relevant To Pharmacies

Where do pharmacies source doxepin and what should be checked when procuring stock?

Major generic suppliers include Mylan and Teva, and various local generics are available in Eastern Europe and elsewhere under different labels.

The Sinequan brand remains in some markets but was discontinued in the USA with generics approved and supplying the market.

In Australia the Doquel brand is supplied by Aspen and equivalent capsule strengths are sold there.

UK pharmacists should check MHRA marketing authorisations and monitor NHS supply channels for shortages and backorders.

Consider multi‑sourcing to manage stock interruptions and verify batch quality, leaflet and SPC versions across generics since excipients and pack sizes may differ.

Maintain supplier qualification records and ensure that imported generics meet UK regulatory standards before dispensing to patients.

Pricing, Payment Pathways & Patient Cost Guidance

NHS Vs Private Purchase And Online Pricing Tips

How much should patients expect to pay and what are the cheapest options?

Doxepin is prescription-only in the UK, and NHS supplies are obtained via prescription; prescription charges vary by nation — free in Scotland, Wales and Northern Ireland, and a standard charge in England unless exemptions apply.

Private prescriptions incur a dispensing fee plus medication cost and may be supplied by online pharmacies where pricing can be competitive but MHRA authorisation and pharmacist oversight should be verified.

Generics typically offer substantial cost savings versus branded products, and pharmacists should advise patients about Prescription Prepayment Certificates in England where relevant.

For cross-border or international purchases, patients must ensure brand strengths and pack sizes match the prescription and avoid non‑verified suppliers.

In our online pharmacy, sinequan is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Product-Page Essentials For An Online Pharmacy

Required Content And UX Elements

What information converts visitors while meeting regulatory expectations?

Product pages should clearly display the INN and any brand names, pack sizes and strengths, and state the Rx status prominently.

Include a dosing quick‑guide, key contraindications and common side effects, storage instructions and manufacturer/supplier details.

Provide downloadable patient leaflets (PDF), a link to the SPC for clinicians and high‑quality pack images with alternate views.

Offer a pharmacist Q&A, a checklist for safe use covering interactions and pregnancy warnings, and a short comparison with common alternatives.

Display trust signals such as MHRA authorisation numbers, verified supply chain logos and a pharmacist contact for consultations to build confidence.

Regulatory, Prescribing & Legal Notes

Prescribing, Reporting And Special Populations

What legal checks and reporting obligations apply to doxepin in the UK?

Doxepin is prescription-only and prescribers should document risk/benefit, especially for older adults and those with cardiac disease.

Report suspected adverse reactions via the MHRA Yellow Card scheme to ensure ongoing pharmacovigilance.

Pregnancy and breastfeeding require specialist advice and doxepin should only be used if clearly needed after risk assessment.

Ensure labelling and patient counselling include the contraindication for MAOI use within 14 days and warnings about driving and alcohol.

Pharmacists must not supply doxepin without a valid prescription and may accept electronic prescriptions and NHS repeat systems where applicable.

Keep documentation of dispensing checks, patient counselling and any contact with prescribers on the pharmacy record as part of standard legal practice.

Delivery Across United Kingdom